Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 839585, 8 pages
http://dx.doi.org/10.1155/2014/839585
Research Article

IVS1 −397T>C Estrogen Receptor α Polymorphism Is Associated with Low-Grade Systemic Inflammatory Response in Type 1 Diabetic Girls

1Department of Immunology, Medical University of Gdańsk, Dębinki 1, 80-211 Gdańsk, Poland
2Clinic of Pediatrics, Department of Diabetology and Endocrinology, Medical University of Gdańsk, 80-211 Gdańsk, Poland

Received 30 September 2013; Accepted 5 December 2013; Published 2 January 2014

Academic Editor: Elaine Hatanaka

Copyright © 2014 Monika Ryba-Stanisławowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Tang, L. Wang, Q. Liao et al., “Genetic associations with diabetes: meta-analyses of 10 candidate polymorphisms,” PLoS One, vol. 8, no. 7, Article ID e70301, 2013. View at Publisher · View at Google Scholar
  2. O. L. Quintero, M. J. Amador-Patarroyo, G. Montoya-Ortiz, A. Rojas-Villarraga, and J.-M. Anaya, “Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity,” Journal of Autoimmunity, vol. 38, no. 2-3, pp. J109–J119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. A. V. Rubtsov, K. Rubtsova, J. W. Kappler, and P. Marrack, “Genetic and hormonal factors in female-biased autoimmunity,” Autoimmunity Reviews, vol. 9, no. 7, pp. 494–498, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. U. Nussinovitch and Y. Shoenfeld, “The role of gender and organ specific autoimmunity,” Autoimmunity Reviews, vol. 11, no. 6-7, pp. A377–A385, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Gleicher and D. H. Barad, “Gender as risk factor for autoimmune diseases,” Journal of Autoimmunity, vol. 28, no. 1, pp. 1–6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. D. A. González, B. B. Díaz, C. Rodríguez Pérez Mdel, A. G. Hernández, B. N. Chico, and A. C. de León, “Sex hormones and autoimmunity,” Immunology Letters, vol. 133, no. 1, pp. 6–13, 2010. View at Publisher · View at Google Scholar
  7. M. J. Polanczyk, B. D. Carson, S. Subramanian et al., “Cutting edge: estrogen drives expiansion of the CD4+CD25 + regulatory T cell compartment,” The Journal of Immunology, vol. 173, no. 4, pp. 2227–2230, 2004. View at Google Scholar · View at Scopus
  8. P. Tai, J. Wang, H. Jin et al., “Induction of regulatory T cells by physiological level estrogen,” Journal of Cellular Physiology, vol. 214, no. 2, pp. 456–464, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Arruvito, M. Sanz, A. H. Banham, and L. Fainboim, “Expansion of CD4+CD25+ and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction,” The Journal of Immunology, vol. 178, no. 4, pp. 2572–2578, 2007. View at Google Scholar · View at Scopus
  10. J. M. Lawson, J. Tremble, C. Dayan et al., “Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes,” Clinical and Experimental Immunology, vol. 154, no. 3, pp. 353–359, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Ryba, N. Marek, Ł. Hak et al., “Anti-TNF rescue CD4+Foxp3+ regulatory T cells in patients with type 1 diabetes from effects mediated by TNF,” Cytokine, vol. 55, no. 3, pp. 353–361, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ryba, K. Rybarczyk-Kapturska, K. Zorena, M. Myśliwiec, and J. Myśliwska, “Lower frequency of CD62Lhigh and higher frequency of TNFR2+ tregs are associated with inflammatory conditions in type 1 diabetic patients,” Mediators of Inflammation, vol. 2011, Article ID 645643, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Luopajärvi, J. Nieminen, J. Ilonen, H. K. Åkerblom, M. Knip, and O. Vaarala, “Expansion of CD4+CD25+FOXP3+ regulatory T cells in infants of mothers with type 1 diabetes,” Pediatric Diabetes, vol. 13, no. 5, pp. 400–407, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Ryba, E. Malinowska, K. Rybarczyk-Kapturska, A. Brandt, M. Myśliwiec, and J. Myśliwska, “The association of the IVS1-397T>C estrogen receptor α polymorphism with the regulatory conditions in longstanding type 1 diabetic girls,” Molecular Immunology, vol. 49, no. 1-2, pp. 324–328, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Targher, L. Bertolini, G. Zoppini, L. Zenari, and G. Falezza, “Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy,” Diabetic Medicine, vol. 22, no. 8, pp. 999–1004, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. R. B. Goldberg, “Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications,” The Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 9, pp. 3171–3182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. K. Lim and G. H. Tesch, “Inflammation in diabetic nephropathy,” Mediators of Inflammation, vol. 2012, Article ID 146154, 12 pages, 2012. View at Publisher · View at Google Scholar
  18. J. F. Navarro-González and C. Mora-Fernández, “The role of inflammatory cytokines in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 19, no. 3, pp. 433–442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Myśliwiec, A. Balcerska, K. Zorena, J. Myśliwska, P. Lipowski, and K. Raczyńska, “The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy,” Diabetes Research and Clinical Practice, vol. 79, no. 1, pp. 141–146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. L. P. Aiello and J.-S. Wong, “Role of vascular endothelial growth factor in diabetic vascular complications,” Kidney International, vol. 77, pp. S113–S119, 2000. View at Google Scholar · View at Scopus
  21. B. F. Schrijvers, A. Flyvbjerg, and A. S. de Vriese, “The role of vascular endothelial growth factor (VEGF) in renal pathophysiology,” Kidney International, vol. 65, no. 6, pp. 2003–2017, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Ryba-Stanisławowska, M. Skrzypkowska, J. Myśliwska, and M. Myśliwiec, “The serum IL-6 profile and Treg/Th17 peripheral cell populations in patients with type 1 diabetes,” Mediators of Inflammation, vol. 2013, Article ID 205284, 7 pages, 2013. View at Publisher · View at Google Scholar
  23. A. Kimura and T. Kishimoto, “IL-6: regulator of Treg/Th17 balance,” European Journal of Immunology, vol. 40, no. 7, pp. 1830–1835, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Cook, “Th17 cells in inflammatory conditions,” The Review of Diabetic Studies, vol. 3, no. 2, pp. 72–75, 2006. View at Google Scholar
  25. E. M. Bradshaw, K. Raddassi, W. Elyaman et al., “Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells,” The Journal of Immunology, vol. 183, no. 7, pp. 4432–4439, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Honkanen, J. K. Nieminen, R. Gao et al., “IL-17 immunity in human type 1 diabetes,” The Journal of Immunology, vol. 185, no. 3, pp. 1959–1967, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Ryba-Stanisławowska, M. Skrzypkowska, M. Myśliwiec, and J. Myśliwska, “Loss of the balance between CD4+Foxp3+ regulatory T cells and CD4+IL17A+ Th17 cells in patients with type 1 diabetes,” Human Immunology, vol. 74, no. 6, pp. 701–707, 2013. View at Publisher · View at Google Scholar
  28. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 31, supplement 1, pp. S55–S60, 2008. View at Publisher · View at Google Scholar
  29. J. Myśliwska, A. Rutkowska, Ł. Hak, J. Siebert, K. Szyndler, and D. Rachoń, “Inflammatory response of coronary artery disease postmenopausal women is associated with the IVS1-397T > C estrogen receptor α polymorphism,” Clinical Immunology, vol. 130, no. 3, pp. 355–364, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. D. M. Herrington, T. D. Howard, K. Bridget Brosnihan et al., “Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein,” Circulation, vol. 105, no. 16, pp. 1879–1882, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. D. M. Herrington, T. D. Howard, G. A. Hawkins et al., “Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease,” The New England Journal of Medicine, vol. 346, no. 13, pp. 967–974, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. D. A. Sukovich, K. Kauser, F. D. Shirley, V. DelVecchio, M. Halks-Miller, and G. M. Rubanyi, “Expression of interleukin-6 in atherosclerotic lesions of male ApoE- knockout mice: inhibition by 17beta-estradiol,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 9, pp. 1498–1505, 1998. View at Google Scholar · View at Scopus
  33. J. Pfeilschifter, R. Köditz, M. Pfohl, and H. Schatz, “Changes in proinflammatory cytokine activity after menopause,” Endocrine Reviews, vol. 23, no. 1, pp. 90–119, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Rachoń, K. Suchecka-Rachoń, Ł. Hak, and J. Myśliwska, “Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women,” Menopause, vol. 13, no. 5, pp. 840–845, 2006. View at Google Scholar · View at Scopus
  35. C. G. Schalkwijk and C. D. A. Stehouwer, “Vascular complications in diabetes mellitus: the role of endothelial dysfunction,” Clinical Science, vol. 109, no. 2, pp. 143–159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. L. E. Benjamin, “Glucose, VEGF-A, and diabetic complications,” The American Journal of Pathology, vol. 158, no. 4, pp. 1181–1184, 2001. View at Google Scholar · View at Scopus
  37. N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. S. A. Yoo, D. G. Bae, J. W. Ryoo et al., “Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes,” The Journal of Immunology, vol. 174, no. 9, pp. 5846–5855, 2005. View at Google Scholar · View at Scopus
  39. D. Verthelyi, “Sex hormones as immunomodulators in health and disease,” International Immunopharmacology, vol. 1, no. 6, pp. 983–993, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Shelbaya, H. Amer, S. Seddik et al., “Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients,” European Review for Medical and Pharmacological Sciences, vol. 16, no. 2, pp. 176–182, 2012. View at Google Scholar · View at Scopus
  41. Z. Huang, B. Yang, Y. Shi et al., “Anti-TNF-α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis,” Cellular Immunology, vol. 279, no. 1, pp. 25–29, 2012. View at Publisher · View at Google Scholar
  42. P. Miossec, “IL-17 and Th17 cells in human inflammatory diseases,” Microbes and Infection, vol. 11, no. 5, pp. 625–630, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Robak, L. Kulczycka-Siennicka, Z. Gerlicz, M. Kierstan, A. Korycka-Wolowiec, and A. Sysa-Jedrzejowska, “Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients,” European Cytokine Network, vol. 24, no. 1, pp. 60–68, 2013. View at Google Scholar
  44. A. S. Chung, X. Wu, G. Zhuang et al., “An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy,” Nature Medicine, vol. 19, pp. 1114–1123, 2013. View at Publisher · View at Google Scholar